Mikhail Blagosklonny’s Groundbreaking Work In Cancer And Aging Research

Mikhail Blagosklonny is an experienced scientist and professor of oncology. Presently, he works at the Roswell Park Cancer Institute. He holds a PhD in experimental medicine and cardiology. Blagosklonny is a graduate of the First Pavlov State Medical University of St. Petersburg. He earned his master’s degree in internal medicine from the same institution.

Mikhail joined the Roswell Park Cancer Institute in 2009. He works for the organization as a professor of oncology. Blagosklonny was appointed due to his extensive experience and research. He became an associate professor at the New York Medical College in 2002. Additionally, Blagosklonny worked as a senior scientist for the Ordway Research Institute. Blagosklonny’s research focuses on anti- aging drugs, cancer, targeted therapies for cancer, and aging mechanisms.

He has been recognized internationally as one of the passionate advocates of Rapamycin, a cancer drug. Blagosklonny has developed a hypothesis on the potential role of TOR signaling in cancer and aging. He has proposed the use of rapamycin given its ability to prolong one’s life.

Blagosklonny serves as the editor-in-chief of several publications, including Oncotarget and Cell Cycle. Moreover, he serves as an associate editor and serves on the editorial board of Cancer Biology and Therapy as well as Cell Death and Differentiation respectively.

He believes that it is possible to have a community that is free from cancer and aging effects. It is for this reason that Blagosklonny has dedicated his time to conducting more research on oncology. As part of his hypothesis, Mikhail zeroes in molecular biology, cellular biology, cell cycle, anti-cancer therapeutics, ontogenesis, clinical investigations, and tumor suppressors.

Additionally, Blagosklonny has made tremendous contributions to science journals. He is an associate editor of different publications, including International Journal for Cancer, PLUS ONE, and American Journal of Pathology. He sees journals as a great medium of enabling people to be aware of the things that are happening. To date, Mikhail Blagosklonny has written over 300 articles. His publications deal with chemotherapeutic engineering, aging hyperfunction theory, and cell cyclotherapy. The scientist has consistently shared his ideas with the public on cancer and aging. His input and contribution of ideas has been integral in cancer and aging research.Read more about Mikhail on Loop.

Leave a Reply

Your email address will not be published. Required fields are marked *